This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ARIAD Pharmaceuticals Inc (ARIA)

NASDAQ: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) -274.16M -220.87M -123.60M 85.25M
Operating Gains/Losses 0.00 0.00 0.00 0.00
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -1.30M -67.00K 373.00K 3.18M
(Increase) Decrease in Inventories -413.00K 0.00 0.00 816.00K
(Increase) Decrease In Other Current Assets -2.11M 0.00 0.00 0.00
(Decrease) Increase In Payables 2.48M 2.66M 2.39M -1.68M
(Decrease) Increase In Other Current Liabilities 4.93M 10.38M 5.11M -850.00K
(Increase) Decrease In Other Working Capital 8.18M 6.83M 1.74M -112.28M
Other Non-Cash Items 36.38M 39.08M 56.11M 25.84M
Net Cash From Continuing Operations -221.88M -153.68M -53.26M 6.42M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -221.88M -153.68M -53.26M 6.42M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 45.00M 44.50M 0.00 0.00
Purchases of Property, Plant & Equipment -8.54M -5.06M -2.12M -2.04M
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments 0.00 -89.55M 0.00 0.00
Other Cash from Investing Activities -10.32M -289.00K 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 26.14M -50.40M -2.12M -2.04M
Issuance of Debt 2.74M 0.00 4.38M 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 6.28M 22.99M 255.93M 60.93M
Repayment of Long-Term Debt -2.12M -1.45M -1.47M -2.04M
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net 306.67M -4.34M -827.00K 0.00
Net Cash From Financing Activities 313.58M 17.20M 258.01M 58.88M
Effect of Exchange Rate Changes -40.00K 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents 117.80M -186.88M 202.63M 63.27M
ARIA News

ARIA ARIAD Pharmaceuticals Inc

Analysts Ratings for ARIA

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 6 6 5 5
Moderate Buy 0 0 0 0
Hold 4 4 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET ARIA ANALYST REPORT

Brokerage Partners

ARIA Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs